



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 78112

Title: Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer having neoadjuvant chemoradiotherapy

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02728463

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Lithuania

Author's Country/Territory: China

Manuscript submission date: 2022-06-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-06-08 08:52

Reviewer performed review: 2022-06-12 08:02

Review time: 3 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input type="checkbox"/>] Anonymous [<input checked="" type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

Dear authors, I would like to congratulate you with this fine study. However, I have few comments. **INTRODUCTION** --I do not think you need to talk on TNT here - it is not the aim of your article. --I would include here or in the **DISCUSSION** the review article on biomolecules as a prognostic factors - Smolskas E, Mikulskytė G, Sileika E, Suziedelis K, Dulskas A. Tissue-Based Markers as a Tool to Assess Response to Neoadjuvant Radiotherapy in Rectal Cancer-Systematic Review. Int J Mol Sci. 2022 May 27;23(11):6040. **MATERIALS and METHODS** --It is not clear to me was is a retrospective study (last paragraph) or prospective (first paragraph)? --Abbreviation NCCN should be defined. --Same with OS. --SPSS manufacturer, city should be included. --Score 1 - what are those "other situations"? **RESULTS** --CRM definition -- "didn't have" these kind of shortenings must be avoided. **DISCUSSION** --some mistype errors should be corrected (didn't, robustest, etc) --if the predictive value was weaker than pTNM, which is always known, what is the purpose of performing additional tests? I would suggest combining all the factors and preparing some nomogram for the precise prognosis. Major limitations: small single center retrospective study with the significant drop-off of the patients.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 78112

Title: Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer having neoadjuvant chemoradiotherapy

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05774393

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2022-06-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-06-15 22:03

Reviewer performed review: 2022-06-16 09:42

Review time: 11 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The study has been done before The prognostic value of a novel serum tumor biomarkers scoring system for clinical Stage II/III rectal cancer patients undergoing neoadjuvant chemoradiotherapy followed by total mesorectal excision The tile is too long it can be : The prognostic value of a novel serum tumor biomarkers scoring system for clinical Stage II/III rectal cancer having neoadjuvant chemoradiotherapy. Do you mean prognostic or predictive value? Pathological response can be evaluated by endoscopic biopsy